UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: For the transition period from ________ to ___ ...

Exhibit 99.1 Quantum-Si Reports First Quarter 2024 Financial Results Executed Full Commercial Launch of Platinum® Instrument Reaf irms Full Year 2024 Financial Guidance BRANFORD, Conn. -- (BUSINESS WIRE) – May 9, 2024 -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced financial results for the first quarter ended March 31, 2024. Press Release Highlights "We concluded our first quarter of 2024 with great momentum on all fronts, i ...

Quantum-Si Incorporated (NASDAQ:QSI) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET Company Participants Katherine Atkinson – Senior Vice President-Commercial Marketing Jeff Hawkins – President and Chief Executive Officer Jeff Keyes – Chief Financial Officer Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Quantum-Si Fourth Quarter and Full Year 2023 Earnings Call. At this time, all partici ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 85-1388175 (State or other jurisdiction of incorp ...

Exhibit 99.1 Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results Finalizing Commercial Readiness for Expected Full Commercial Launch by the End of Q1 2024 Releases Full Year 2024 Financial Guidance BRANFORD, Conn. -- (BUSINESS WIRE) – Feb. 29, 2024 -- Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced financial results for the fourth quarter and full year ended December 31, 2023. Press Release Highlights "We made ...

Quantum-Si Incorporated (NASDAQ:QSI) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Katherine Atkinson - SVP, Commercial Marketing Jeff Hawkins - President and Chief Executive Officer Jeff Keyes - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Swayampakula Ramakanth - H.C. Wainwright Operator Good day and thank you for standing by. Welcome to the Quantum-Si Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 85-1388175 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-39486 QUANTUM-SI INCORPORATED (Exact name of registrant as specified in its charter) Delaware 85-1388175 (Sta ...

Quantum-Si incorporated (NASDAQ:QSI) Q2 2023 Earnings Conference Call August 7, 2023 8:30 AM ET Company Participants Juan Avendano - Head, Investor Relations Jeff Hawkins - Chief Executive Officer Jeff Keyes - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Yuan Zhi - B. Riley Swayampakula Ramakanth - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by. Welcome to the Quantum-Si Second Quarter 2023 Earnings Call. [Operator Instructions] Please be ad ...

Financial Data and Key Metrics Changes - Revenue for Q1 2023 was $254,000, marking the first revenue recognized from the sale of Platinum instruments and kits, slightly above internal plans [25][35] - Gross profit for Q1 2023 was $124,000, resulting in a gross margin of 48.8%, driven primarily by the Platinum instrument product mix [35][36] - Operating expenses increased to $29.3 million in Q1 2023 from $27.1 million in Q1 2022, mainly due to higher selling, general, and administrative expenses [36] - Net loss for Q1 2023 was $23.6 million, an improvement from a net loss of $35.2 million in Q1 2022 [37] - Adjusted EBITDA for Q1 2023 was a loss of $23.7 million, compared to a loss of $27.4 million in Q1 2022 [37] - As of March 31, 2023, the company had $322.1 million in cash and cash equivalents and investments in marketable securities [37] Business Line Data and Key Metrics Changes - Customer orders in Q1 2023 totaled $449,000, slightly above internal plans, with a delay in shipping two international orders affecting revenue recognition [25][36] - The sales funnel is developing positively, with a mix of academic research centers, biotech, pharma, industrial, and government customers showing interest [5][46] Market Data and Key Metrics Changes - The advanced sales funnel consists of approximately 60% U.S. customers and 40% European customers, indicating strong interest from European markets [4] - The company is seeing significant interest in proteoform and post-translational modification (PTM) analysis, protein identification, and antibody validation [5][6] Company Strategy and Development Direction - The company aims to commercialize its Platinum, Carbon, and 2M chip products, with a controlled rollout to ensure customer satisfaction [24][34] - Plans to enhance outbound marketing and direct sales efforts to support revenue growth in the second half of the year [9][38] - The company is focused on innovation in protein sequencing and has established strategic partnerships with key opinion leaders [10][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong customer interest and the potential for revenue acceleration in the second half of 2023 [38][42] - The company expects Q2 orders to be similar to Q1, with gross margins anticipated to remain consistent with Q1 levels [15][43] - Management is committed to maintaining fiscal discipline while investing in commercial team expansion and marketing programs [16][36] Other Important Information - A new Chief Financial Officer, Jeff Keyes, will join the company on May 15, 2023, bringing extensive experience in public company management [17] - The Carbon sample prep instrument is on track for beta testing in Q2 2023, with a launch expected in the second half of the year [11] Q&A Session Summary Question: Who are the early buyers of the Platinum system and what are the initial applications? - Early customers are primarily from academic research centers, with interest also growing in pharma, biotech, and industrial applications [46][47] Question: What is the expected revenue guidance for the second half of the year? - The company expects revenue to accelerate in the second half based on business funnel visibility and increased marketing efforts [42][43] Question: How is the pricing strategy for the Platinum system evolving? - The company is monitoring pricing but has not seen significant pressure, maintaining most transactions at or near list pricing [63] Question: What are the early customer experiences with the Platinum system? - Early customer feedback has been positive, with no significant variation in performance compared to internal testing [66][67] Question: How will the Carbon instrument impact the workflow and attach rate? - The Carbon instrument is expected to enhance automation and efficiency, with further data from beta testing to inform its impact on attach rates [69]